Search
Xilio Therapeutics Inc
XLOAdd to Watchlist
9.220USD
+0.050+0.55%
Market hours （ET）Quotes delayed by 15 min
60.67MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Xilio Therapeutics Inc is 10.00, ranking 1 out of 387 in the Biotechnology & Medical Research industry. The average price target is 2.00, with a high of 2.00 and a low of 2.00.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
20.000
Target Price
+118.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Xilio Therapeutics Inc
XLO
1
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Xilio Therapeutics Inc's expected revenue for the next quarter?
Xilio Therapeutics Inc's expected revenue is 4.84M.
What is Xilio Therapeutics Inc's price target?
Analysts forecast that Xilio Therapeutics Inc's price target is USD 2.00, with the highest forecast at USD 2.00 and the lowest forecast at USD 2.00.
How have Xilio Therapeutics IncXLO's recent earnings per share performed?
The market expectation was USD -0.33, while Xilio Therapeutics IncXLO's earnings per share (EPS) for the previous quarter was USD -0.58. EPS for the next quarter is expected at USD -0.92.
What is the analyst rating for Xilio Therapeutics Inc?
Based on the ratings of Xilio Therapeutics Inc's stock from 1 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.